The role of extracellular vesicles in acquisition of resistance to therapy in glioblastomas  

作　　者：Anudeep Yekula Abigail Taylor Alexandra Beecroft Keiko M.Kang Julia L.Small Koushik Muralidharan Zachary Rosh Bob S.Carter Leonora Balaj 

机构地区：[1]Department of Neurosurgery,Massachusetts General Hospital,Boston,MA 02114,USA [2]Brigham Young University,Provo,UT 84602,USA

出　　处：《Cancer Drug Resistance》2021年第1期1-16,共16页癌症耐药（英文）

摘　　要：Glioblastoma(GBM)is the most aggressive primary brain tumor with a median survival of 15 months despite standard care therapy consisting of maximal surgical debulking,followed by radiation therapy with concurrent and adjuvant temozolomide treatment.The natural history of GBM is characterized by inevitable recurrence with patients dying from increasingly resistant tumor regrowth after therapy.Several mechanisms including inter-and intratumoral heterogeneity,the evolution of therapy-resistant clonal subpopulations,reacquisition of stemness in glioblastoma stem cells,multiple drug efflux mechanisms,the tumor-promoting microenvironment,metabolic adaptations,and enhanced repair of drug-induced DNA damage have been implicated in therapy failure.Extracellular vesicles(EVs)have emerged as crucial mediators in the maintenance and establishment of GBM.Multiple seminal studies have uncovered the multi-dynamic role of EVs in the acquisition of drug resistance.Mechanisms include EV-mediated cargo transfer and EVs functioning as drug efflux channels and decoys for antibody-based therapies.In this review,we discuss the various mechanisms of therapy resistance in GBM,highlighting the emerging role of EV-orchestrated drug resistance.Understanding the landscape of GBM resistance is critical in devising novel therapeutic approaches to fight this deadly disease.

关 键 词：GLIOBLASTOMA RESISTANCE extracellular vesicles TEMOZOLOMIDE radiation 

分 类 号：R73[医药卫生—肿瘤]